ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO311

Characteristics of the First 500 Tablo Home Hemodialysis Users

Session Information

  • Home Dialysis - I
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Dunning, Stephan C., Outset Medical, San Jose, California, United States
  • Kirk, Hunter, Outset Medical, San Jose, California, United States
  • D'Alessandri-Silva, Cynthia J., Outset Medical, San Jose, California, United States
  • Aragon, Michael A., Outset Medical, San Jose, California, United States

The Tablo® Hemodialysis System was cleared for home hemodialysis (HHD) use in March 2020, offering dialysis patients the first novel technology for HHD since 2005. In the 2022 ESRD PPS Final Rule, the Centers for Medicare and Medicaid Services (CMS) designated Tablo a “substantial clinical improvement” over the incumbent technology based on increased treatment flexibility, higher treatment adherence, higher modality retention and improvement in patient quality of life. As adoption continues to grow, we sought to characterize the first 500 users in the Tablo HHD population.


We collected user-reported demographics and geographic information among the first 500 Tablo HHD users. Data include age, sex, race/ethnicity, employment status and Zip Code. Using Zip Code, we evaluated neighborhood characteristics such as Social Deprivation Index (SDI) and Rural status using RUCA 4+. Population characteristics are compared to similar data from the 2022 USRDS Annual Data Report, where feasible. The results are descriptive only using MS Excel. No statistical significance tests were performed.


Across the basic demographics of age sex and race/ethnicity, the Tablo HHD population and USRDS HHD appear to have similar characteristics with several favorable trends. The first 500 Tablo HHD users versus USRDS HHD are:

● Slightly older: 35.2% vs 29.0%, Age 65+ respectively.
● Slightly more racially/ethnically diverse: 45.6% vs 52.8% White, 19.5% vs 30.6% Black, 11.5% vs 3.0% Asian and 18.1% vs 11.1% Hispanic, respectively.
● More unemployed, fewer retired: 33.5% vs 18.6% Unemployed, 38.8% vs 54.3% Retired, respectively.

Socio-economic data show equitable adoption across strata, with SDI 1-33 (37.2%), SDI 34-66 (32.2%) and SDI 67-100 (30.6%). Rural and Urban status are 14.4% and 85.6%, respectively.


Continued improvement in equity across ethnic, racial and socio-economic status among all HHD patients is critical to successful expansion of home adoption in the US. The first 500 Tablo Home Hemodialysis users have similar characteristics to the overall HHD population reported by the USRDS with early favorable trends toward diverse and equitable adoption across racial and socio-economic groups.


  • Commercial Support – Outset Medical